IARTHIGH SIGNALFINANCIAL10-K

IART experienced a catastrophic swing from modest profitability to massive losses, with net income plummeting from -$6.9M to -$516.5M while operating income collapsed from $28.4M to -$493.4M.

This represents a fundamental deterioration in the company's operational performance, with losses expanding by over 7,000% despite significant gross profit growth. The magnitude of this swing suggests either major write-downs, restructuring charges, or severe operational disruption that investors need to understand immediately.

Comparing 2026-02-26 vs 2025-02-25View on EDGAR →
FINANCIAL ANALYSIS

While IART achieved impressive gross profit growth of 262% to $851M, this was completely overwhelmed by operational expenses that drove operating income deeply negative and net losses to over half a billion dollars. The company simultaneously reduced current liabilities by 51% and saw stockholders' equity decline by 33%, while dramatically cutting share buybacks and operating cash flow fell 61%. This financial profile suggests a company undergoing major restructuring or facing significant one-time charges that have masked what otherwise appears to be improving revenue performance.

FINANCIAL STATEMENT CHANGES
Net Income
P&L
-7337.7%
-$6.9M-$516.5M

Net income declined 7337.7% — review whether driven by operations, interest costs, or non-recurring items.

Operating Income
P&L
-1836.5%
$28.4M-$493.4M

Operating income deteriorated sharply — investigate whether driven by one-time charges or structural cost issues.

Gross Profit
P&L
+261.5%
$235.4M$851.0M

Gross profit expanding — improving pricing power or product mix shift toward higher-margin offerings.

Share Buybacks
Cash Flow
-99.6%
$52.5M$221K

Buyback activity reduced 99.6% — capital being redeployed elsewhere or cash conservation underway.

Operating Cash Flow
Cash Flow
-61.1%
$129.4M$50.4M

Operating cash flow fell 61.1% — earnings quality concerns; investigate working capital changes and non-cash items.

Current Liabilities
Balance Sheet
-50.6%
$922.1M$456.0M

Current liabilities reduced — improved short-term financial position and working capital health.

Stockholders Equity
Balance Sheet
-32.5%
$1.5B$1.0B

Equity declined sharply — large losses, buybacks, or write-downs reducing book value significantly.

R&D Expense
P&L
+23%
$63.5M$78.0M

R&D investment increased 23% — signals commitment to future product development, though near-term margin impact.

Capital Expenditure
Cash Flow
-22%
$104.4M$81.4M

Capex reduced 22% — investment cycle winding down or capital discipline; may improve near-term free cash flow.

Inventory
Balance Sheet
+14.8%
$429.1M$492.7M

Inventory built 14.8% — monitor whether demand supports this build or if write-downs may follow.

LANGUAGE CHANGES
NEW — 2026-02-26
PRIOR — 2025-02-25
ADDED
Management's Discussion and Analysis of Financial Condition and Results of Operations 40 Item 7A.
Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters 56 Item 13.
BUSINESS OVERVIEW Integra LifeSciences Holdings Corporation is a global medical technology company dedicated to restoring lives.
We are advancing transformational care through impactful innovation and our portfolio of highly differentiated technologies is trusted by healthcare professionals to deliver transformative care.
The CSS segment, which represents approximately 70% of our total revenue, consists of market-leading technologies and instrumentation used for a wide range of specialties, such as neurosurgery, neurocritical care, and otolaryngology, commonly referred to as ear, nose, and throat ( ENT ).
+7 more — sign up free →
REMOVED
Management's Discussion and Analysis of Financial Condition and Results of Operations 38 Item 7A.
Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matte rs 57 Item 13.
and international governmental, regulatory, fiscal, monetary and public health responses to such crises; and other risk factors described in Item 1A.
BUSINESS OVERVIEW Integra LifeSciences Holdings Corporation was founded in 1989 and is a leading global medical technology company innovating treatment pathways to advance patient outcomes and set new standards of surgical, neurologic, ear, nose, and throat ( ENT ) and regenerative care.
Integra products are sold in more than 120 countries through a direct sales force as well as distributors and wholesalers.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
PNRGHIGHPNRG achieved exceptional profitability improvement with net income surging 2,21...
2026-04-16
BNAIHIGHBNAI underwent a dramatic reverse stock split that reduced share count by 86% wh...
2026-04-16
LAKEHIGHLAKE's financial performance deteriorated significantly with operating losses wo...
2026-04-16
NXXTHIGHNextNRG experienced massive financial deterioration with operating losses explod...
2026-04-16
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →